Candel to Present Accumulating Phase 3 CAN-2409+EBRT Benefits in Prostate Cancer
Candel Therapeutics will present extended follow-up data from its PrTK03 phase 3 trial showing accumulating benefits of CAN-2409 plus prodrug with EBRT in intermediate- to high-risk localized prostate cancer. The oral presentation is set for May 15 in the Practice-changing Clinical Trials plenary at the AUA 2026 Annual Meeting.
1. Presentation Acceptance and Schedule
Candel has secured an oral plenary slot in the Practice-changing, Paradigm-shifting Clinical Trials in Urology session at the American Urological Association Annual Meeting on May 15, 2026, from 11:30 AM to 11:40 AM ET in Washington, D.C.
2. Phase 3 Trial Update
Extended follow-up from the PrTK03 randomized phase 3 trial in intermediate- to high-risk localized prostate cancer shows accumulating benefit for patients receiving CAN-2409 plus prodrug alongside external beam radiation therapy.
3. Immunotherapy Pipeline and Designations
Candel’s clinical-stage immunotherapy pipeline includes CAN-2409, which has Fast Track and Regenerative Medicine Advanced Therapy designations for localized prostate cancer, and HSV-based CAN-3110, currently in phase 1b trials for glioma with Fast Track and Orphan Drug designations.